Boundless Bio
spyglass reveals cancer targets both novel and validated that intersect distinct nodes of | Boundless Bio
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2024
Slide
23 of 51
Related slides by other companies
Nuvalent
Investor Presentation
February 2024
pipeline advancing a portfolio of potentially best in class products with complementary initial indications in lead indication product candidate discovery enabling phase phase anticipated milestones rights open enrolling phase portion phase trial data update medical meeting alk open enrolling phase portion phase trial phase initiation data update medical meeting her phase initiation undisclosed targets additional discovery research programs ongoing key milestone achieved planned milestone | Nuvalent
AstraZeneca
Investor Event
June 2023
duo phase in advanced endometrial cancer | AstraZeneca
AN2 Therapeutics
IPO
March 2022
pipeline targets high unmet needs in rare chronic and serious infectious diseases lung disease boron chemistry approach enables targeting of novel biological targets mid phase topline data japan attest as an therapeutics | AN2 Therapeutics
Exscientia
Investor Presentation
October 2023
why are our clinical candidates different | Exscientia
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io